GlassScriptPhysician profile
Andrew Norato
NPI 1023655628
$7,111.21
in general payments reported to CMS, 2019-2025
37 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $1,527 · 2023: $1,091 · 2024: $1,873 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,976.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,816.35 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $771.02 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $739.95 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $555.98 | 2022-2025 | |
| Abbvie INC. | $478.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.18 | 2021-2025 | Jardiance |
| Amgen INC. | $249.99 | 2021-2025 | Evenity, Krystexxa, Otezla |
| Dexcom, INC. | $228.66 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $166.31 | 2021-2025 | Shingrix, Arexvy |
| Genentech USA, INC. | $163.81 | 2022 | |
| Janssen Biotech, INC. | $156.60 | 2024-2025 | Erleada, Akeega |
| Otsuka America Pharmaceutical, INC. | $147.87 | 2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $135.74 | 2022 | |
| Axsome Therapeutics, INC. | $134.68 | 2023 | Auvelity |
| Pfizer INC. | $133.78 | 2022-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Norato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.